1) Describe how wild-type BRCA2 is thought to be involved in controlling the repair of DNA double-stranded breaks (DSB) by homologous recombination in mammalian cells? 

2) Can you propose a possible therapeutic strategy(ies) that might correct any homologous recombination deficiencies in cells expressing BRCA26174delt protein?| 

3) Explain the concept of “synthetic lethality”. How might you use this strategy to eliminate cells expressing BRCA26174delt protein.